HC Wainwright Forecasts Alpha Cognition Q1 Earnings

Alpha Cognition, Inc. (NASDAQ:ACOG) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for Alpha Cognition in a note issued to investors on Tuesday, March 18th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.72) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. HC Wainwright also issued estimates for Alpha Cognition’s Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.02) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.29) EPS and FY2026 earnings at ($1.67) EPS.

Alpha Cognition Price Performance

NASDAQ ACOG opened at $5.37 on Thursday. The stock’s 50-day simple moving average is $5.90. Alpha Cognition has a twelve month low of $4.66 and a twelve month high of $7.00. The stock has a market capitalization of $86.03 million, a P/E ratio of -2.10 and a beta of 2.50.

Hedge Funds Weigh In On Alpha Cognition

Several large investors have recently added to or reduced their stakes in the business. Solas Capital Management LLC purchased a new position in Alpha Cognition during the fourth quarter worth about $8,096,000. Sphera Funds Management LTD. purchased a new position in Alpha Cognition during the fourth quarter worth about $3,652,000. Alyeska Investment Group L.P. purchased a new position in Alpha Cognition during the fourth quarter worth about $2,356,000. Altium Capital Management LLC purchased a new position in Alpha Cognition during the fourth quarter worth about $1,620,000. Finally, Rosalind Advisors Inc. acquired a new stake in Alpha Cognition during the fourth quarter worth about $1,489,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.